These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 28608740

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    Puig L, Notario J, Jiménez-Morales A, Moreno-Ramírez D, López-Ferrer A, Gozalbo I, Prades M, Lizán L, Blanch C.
    J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
    Igarashi A, Kuwabara H, Fahrbach K, Schenkel B.
    J Dermatolog Treat; 2013 Oct; 24(5):351-5. PubMed ID: 22632451
    [Abstract] [Full Text] [Related]

  • 9. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 10. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [Abstract] [Full Text] [Related]

  • 11. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R, Iwasaki K, Tang W, Mahlich J.
    BMC Dermatol; 2018 Jul 11; 18(1):5. PubMed ID: 29996929
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT, Shojania K, Dutz J, Tsao NW.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jul 11; 16(2):153-66. PubMed ID: 26681527
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA.
    J Med Econ; 2020 Jan 11; 23(1):80-85. PubMed ID: 31294641
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.